<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493947</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.40173</org_study_id>
    <nct_id>NCT01493947</nct_id>
  </id_info>
  <brief_title>CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study</brief_title>
  <acronym>ATTRACT</acronym>
  <official_title>Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objectives:

        -  To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream
           in subjects with papulopustular rosacea after 16-week topical treatment.

        -  And to compare, for subjects initially successfully treated by 16 weeks treatment,
           Ivermectin 1 % cream versus metronidazole 0.75% cream during a 36-week extension period
           by assessing, the time of first relapse, the relapse rate, and the number of days free
           of treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Inflammatory Lesions From Baseline to Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period</description>
  </primary_outcome>
  <other_outcome>
    <measure>Time to Relapse</measure>
    <time_frame>Week 16 up to Week 52</time_frame>
    <description>Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">962</enrollment>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>Ivermectin 1% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole 0.75% cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 1% cream</intervention_name>
    <description>Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.</description>
    <arm_group_label>Ivermectin 1% cream</arm_group_label>
    <other_name>Soolantra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 0.75% cream</intervention_name>
    <description>Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.</description>
    <arm_group_label>Metronidazole 0.75% cream</arm_group_label>
    <other_name>Metronidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with papulopustular rosacea scored 3 (moderate) or 4 (severe) according to
             the Investigator Global Assessment (IGA),

          -  Subjects with at least 15 but not more than 70 inflammatory lesions (papules and
             pustules) on the face.

        Exclusion Criteria:

          -  Subjects with particular forms of rosacea (rosacea conglobate, rosacea fulminant,
             isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that
             may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial
             keratosis pilar, or seborrheic dermatitis and acne,

          -  Subjects with rosacea with more than two nodules on the face.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Chomutov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Invetigational site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Praha 1</city>
        <zip>110 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Slany</city>
        <zip>27 401</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13 507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64 297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Langenau</city>
        <zip>89 129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Mahlow</city>
        <zip>15 831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>052</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1238</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Pecel</city>
        <zip>21 19</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Tirgu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Berkshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bexhill</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Nuneaton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <results_first_submitted>June 29, 2015</results_first_submitted>
  <results_first_submitted_qc>September 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2015</results_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ivermectin</title>
          <description>Ivermectin applied once daily on the face during 16-week</description>
        </group>
        <group group_id="P2">
          <title>Metronidazole 0.75% Cream</title>
          <description>Metronidazole 0.75% cream applied twice daily on the face during 16-week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period A Efficacy and Safety Data</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="478"/>
                <participants group_id="P2" count="484"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="446"/>
                <participants group_id="P2" count="456"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period B Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="399">Only 399 /446 subjects were eligible to enter in Period B (i.e IGA=0 or1 at end of Period A).</participants>
                <participants group_id="P2" count="358">358 / 456 subjects were eligible to enter in Period B (i.e IGA =0 or 1 at end of Period A).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="366"/>
                <participants group_id="P2" count="326"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ivermectin</title>
          <description>Ivermectin: Ivermectin applied once daily on the face during 16-week plus 36-week extension period.</description>
        </group>
        <group group_id="B2">
          <title>Metronidazole 0.75% Cream</title>
          <description>Metronidazole 0.75% cream: Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="478"/>
            <count group_id="B2" value="484"/>
            <count group_id="B3" value="962"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="394"/>
                    <measurement group_id="B2" value="398"/>
                    <measurement group_id="B3" value="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Inflammatory Lesions From Baseline to Week 16</title>
        <description>Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period</description>
        <time_frame>Baseline and Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin</title>
            <description>Ivermectin: Ivermectin applied once daily on the face during 16-week plus 36-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Metronidazole 0.75% Cream</title>
            <description>Metronidazole 0.75% cream: Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Inflammatory Lesions From Baseline to Week 16</title>
          <description>Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83" spread="26"/>
                    <measurement group_id="O2" value="-73.7" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Relapse</title>
        <description>Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.</description>
        <time_frame>Week 16 up to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CD5024</title>
            <description>CD5024: CD5024 applied once daily on the face during 16-week plus 36-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Metronidazole 0.75% Cream</title>
            <description>Metronidazole 0.75% cream: Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse</title>
          <description>Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.</description>
          <units>Median days to relapse</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="113" upper_limit="165"/>
                    <measurement group_id="O2" value="85" lower_limit="85" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One subject received Ivermectin in Period A,but after relapse received metronidazole in Period B. This subject was counted in each group, but the Adverse Events (AEs) are counted according to their onset date.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ivermectin 1% Cream Period A</title>
          <description>Ivermectin applied once daily on the face during 16-week</description>
        </group>
        <group group_id="E2">
          <title>Metronidazole 0.75% Cream Period A</title>
          <description>Metronidazole 0.75% cream applied twice daily on the face during 16-week</description>
        </group>
        <group group_id="E3">
          <title>Ivermectin 1% Cream Period B</title>
          <description>36-week extension period :only subjects with an IGA of 0 or 1 at Week 16 (i.e., at the last visit of Period A) were eligible</description>
        </group>
        <group group_id="E4">
          <title>Metronidazole 0.75% Cream Period B</title>
          <description>36-week extension period : only subjects with an IGA of 0 or 1 at Week 16 (i.e., at the last visit of Period A) were eligible.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="399"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Vitello-Intestinal Duct Remnant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eczema Infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain Herniation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Whiplash Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoathritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolitiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="399"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharingitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="478"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="484"/>
                <counts group_id="E3" events="37" subjects_affected="37" subjects_at_risk="399"/>
                <counts group_id="E4" events="39" subjects_affected="39" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="478"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="484"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="399"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="478"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="399"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="478"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="478"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="399"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="478"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="399"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="399"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="478"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="399"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="399"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="478"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="484"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="399"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="478"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="399"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="478"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="478"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="399"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Galderma CPM</name_or_title>
      <organization>Galderma R&amp;D</organization>
      <phone>00 33 4 93 95 70 70</phone>
      <email>clinicaltrials@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

